相关实验视频
Updated: Jun 24, 2025

08:49
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
16.4K
术后克罗恩氏病复发风险和最佳生物时间在经过伊利奥科利切除后的临时转移后
Abel Joseph1, Salam P Bachour2, Ravi Shah3
1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Inflammatory bowel diseases
|June 6, 2024
概括
在大眼切除后,克罗恩病 (CD) 的术后复发是常见的. 预期的临时转移 (ITD) 并没有增加放射或内镜复发,但手术复发的风险更高. 在静脉管逆转之前,生物治疗的时间要求对高风险患者进行考虑.
科学领域:
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
- 炎症性肠道疾病研究研究
背景情况:
- 经过大眼切除后克罗恩病 (CD) 的术后复发是一个重大的临床挑战.
- 虽然原发性解剖切除是常见的,但用于高风险患者,用于缓解解剖切除并发症的有意临时转移 (ITD).
- 转移对CD复发的影响和生物预防的最佳时间仍然是研究领域.
研究的目的:
- 为了评估转移状态和术后CD复发风险之间的关联.
- 评价生物预防时间相对于骨髓摘除 (OT) 对ITD患者复发的影响.
主要方法:
- 对793名经过大眼切除术的CD患者进行了回顾性队列研究 (2009-2020年).
- 根据连续性状况分组患者:初级瘤与ITD.
- 倾向性评分加权匹配和多变量回归分析被用来比较群体之间的复发结果 (放射,内镜,手术,复合),调整风险因素.
主要成果:
- 在倾向分数匹配后,ITD与放射或内镜复发的增加无关,但显示了手术复发的风险较高 (aHR, 1.61;95% CI, 1.02-2.54).
- 在ITD组中,56.1%的患者在OT后开始服用生物药物,11.4%的患者在OT前服用生物药物,32.4%的患者没有服用术后生物药物.
- 在OT之前开始生物预防,与OT后开始相比,并没有显著减少OT后复合复发 (52%对70.7%;P=.09).
结论:
- 在临床上有指示时,应进行大肠切除后的转移,因为它并不总是与术后复发风险的增加有关.
- 需要转移的患者患病复发的风险很高,在静脉栓逆转之前开始生物疗法可能是有益的策略.
- 需要进一步的研究,以优化生物预防的时间,在患者ITD经历了Crohn's病的骨髓切除.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
139
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
139
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Appendicitis-II: Diagnostic Studies and Management
74
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
74

